Antibody-based therapies in systemic lupus erythematosus

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 829-846

  Iikuni, Noriko ^a   La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AMG 557; AMG 811; ANTOVA; ATACICEPT; ATLIZUMAB; AZATHIOPRINE; BELATACEPT; BELIMUMAB; BG 9588; BRIOBACEPT; CYCLOPHOSPHAMIDE; ECULIZUMAB; EFALIZUMAB; EPRATUZUMAB; ETANERCEPT; ETI 201; GLUCOCORTICOID; IMMU 106; INFLIXIMAB; MEDI 545; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; RUPLIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; CYTOKINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY PRODUCTION; B CELL LYMPHOMA; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENICITY; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; LYMPHOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; B LYMPHOCYTE; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 68849098147     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788452568     Document Type: Review

References (160)

1. Hudson, P.; Souriau, C. Engineered antibodies. Nat. Med., 2003, 9 (1), 129-34.
2. Glennie, M.; Johnson, P. Clinical trials of antibody therapy. Immunol. Today, 2000, 21 (8), 403-10.
3. Shapiro, M.; Swann, P.; Hartsough, M. In Handbook of Therapeutic Antibodies; Dubel, Ed.; Wiley-VCH: 2007; pp. 277-300.
4. Reichert, J.; Rosensweig, C.; Faden, L.; Dewitz, M. Monoclonal antibody successes in the clinic. Nat. Biotechnol., 2005, 23 (9), 1073-8.
5. Chan, O.; Hannum, L.; Haberman, A.; Madaio, M.; Shlomchik, M. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med., 1999, 189 (10), 1639-48.
6. Mamula, M.; Fatenejad, S.; Craft, J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J. Immunol., 1994, 152 (3), 1453-61.
7. Linton, P.; Harbertson, J.; Bradley, L. A critical role for B cells in the development of memory CD4 cells. J. Immunol., 2000, 165 (10), 5558-65.
8. Bubien, J.; Zhou, L.; Bell, P.; Frizzell, R.; Tedder, T. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell. Biol., 1993, 121 (5), 1121-32.
9. Press, O.; Appelbaum, F.; Ledbetter, J.; Martin, P.; Zarling, J.; Kidd, P.; Thomas, E. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood, 1987, 69 (2), 584-91.
10. Reff, M.; Carner, K.; Chambers, K.; Chinn, P.; Leonard, J.; Raab, R.; Newman, R.; Hanna, N.; Anderson, D. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 1994, 83 (2), 435-45.
11. Silverman, G.; Weisman, S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum., 2003, 48 (6), 1484-92.
12. Emery, P.; Fleischmann, R.; Filipowicz-Sosnowska, A.; Schechtman, J.; Szczepanski, L.; Kavanaugh, A.; Racewicz, A.; van Vollenhoven, R.; Li, N.; Agarwal, S.; Hessey, E.; Shaw, T. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum., 2006, 54 (5), 1390-400.
13. Cohen, S.; Emery, P.; Greenwald, M.; Dougados, M.; Furie, R.; Genovese, M.; Keystone, E.; Loveless, J.; Burmester, G.; Cravets, M.; Hessey, E.; Shaw, T.; Totoritis, M. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum., 2006, 54 (9), 2793-806.
14. Chambers, S.; Isenberg, D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus, 2005, 14 (3), 210-4.
15. Anolik, J.; Barnard, J.; Cappione, A.; Pugh-Bernard, A.; Felgar, R.; Looney, R.; Sanz, I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum., 2004, 50 (11), 3580-90.
16. Looney, R.; Anolik, J.; Campbell, D.; Felgar, R.; Young, F.; Arend, L.; Sloand, J.; Rosenblatt, J.; Sanz, I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II doseescalation trial of rituximab. Arthritis Rheum., 2004, 50 (8), 2580-9.
17. Tanaka, Y.; Yamamoto, K.; Takeuchi, T.; Nishimoto, N.; Miyasaka, N.; Sumida, T.; Shima, Y.; Takada, K.; Matsumoto, I.; Saito, K.; Koike, T. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol., 2007, 17 (3), 191-7.
18. Ng, K.; Cambridge, G.; Leandro, M.; Edwards, J.; Ehrenstein, M.; Isenberg, D. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis., 2007, 66 (9), 1259-62.
19. Jónsdóttir, T.; Gunnarsson, I.; Risselada, A.; Henriksson, E.; Klareskog, L.; van Vollenhoven, R. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis., 2008, 67 (3), 330-4.
20. Albert, D.; Dunham, J.; Khan, S.; Stansberry, J.; Kolasinski, S.; Tsai, D.; Pullman-Mooar, S.; Barnack, F.; Striebich, C.; Looney, R.; Prak, E.; Kimberly, R.; Zhang, Y.; Eisenberg, R. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann. Rheum. Dis., 2008, 67 (12), 1724-31.
21. Roll, P.; Palanichamy, A.; Kneitz, C.; Dorner, T.; Tony, H. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum., 2006, 54 (8), 2377-86.
22. Tanaka, Y. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Intern. Med., 2007, 46 (16), 1313-5.
23. Sfikakis, P.; Boletis, J.; Lionaki, S.; Vigklis, V.; Fragiadaki, K.; Iniotaki, A.; Moutsopoulos, H. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum., 2005, 52 (2), 501-13.
24. Edwards, J.; Szczepanski, L.; Szechinski, J.; Filipowicz-Sosnowska, A.; Emery, P.; Close, D.; Stevens, R.; Shaw, T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350 (25), 2572-81.
25. Agarwal, A.; Vieira, C.; Book, B.; Sidner, R.; Fineberg, N.; Pescovitz, M. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am. J. Transplant., 2004, 4 (8), 1357-60.
26. Sfikakis, P.; Boletis, J.; Tsokos, G. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol., 2005, 17 (5), 550-7.
27. Cambridge, G.; Leandro, M.; Edwards, J.; Ehrenstein, M.; Salden, M.; Bodman-Smith, M.; Webster, A. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum., 2003, 48 (8), 2146-54.
28. Anolik, J.; Campbell, D.; Felgar, R.; Young, F.; Sanz, I.; Rosenblatt, J.; Looney, R. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum., 2003, 48 (2), 455-9.
29. Hennigan, S.; Channick, R.; Silverman, G. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus, 2008, 17 (8), 754-6.
30. Ng, K.; Leandro, M.; Edwards, J.; Ehrenstein, M.; Cambridge, G.; Isenberg, D. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann. Rheum. Dis., 2006, 65 (7), 942-5.
31. Rückert, A.; Glimm, H.; Lübbert, M.; Grüllich, C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus, 2008, 17 (8), 757-60.
32. Nwobi, O.; Abitbol, C.; Chandar, J.; Seeherunvong, W.; Zilleruelo, G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr. Nephrol., 2008, 23 (3), 413-9.
33. Boren, E.; Cheema, G.; Naguwa, S.; Ansari, A.; Gershwin, M. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J. Autoimmun., 2008, 30 (1-2), 90-8.
34. Freim Wahl, S.; Folvik, M.; Torp, S. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin. Neuropathol., 2007, 26 (2), 68-73.
35. Stein, R.; Qu, Z.; Chen, S.; Rosario, A.; Shi, V.; Hayes, M.; Horak, I.; Hansen, H.; Goldenberg, D. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res., 2004, 10 (8), 2868-78.
36. Sato, S.; Miller, A.; Inaoki, M.; Bock, C.; Jansen, P.; Tang, M.; Tedder, T. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity, 1996, 5 (6), 551-62.
37. Poe, J.; Fujimoto, M.; Jansen, P.; Miller, A.; Tedder, T. CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J. Biol. Chem., 2000, 275 (23), 17420-7.
38. Engel, P.; Nojima, Y.; Rothstein, D.; Zhou, L.; Wilson, G.; Kehrl, J.; Tedder, T. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J. Immunol., 1993, 150 (11), 4719-32.
39. Sato, S.; Tuscano, J.; Inaoki, M.; Tedder, T. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin. Immunol., 1998, 10 (4), 287-97.
40. Tuscano, J.; Riva, A.; Toscano, S.; Tedder, T.; Kehrl, J. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood, 1999, 94 (4), 1382-92.
41. Carnahan, J.; Wang, P.; Kendall, R.; Chen, C.; Hu, S.; Boone, T.; Juan, T.; Talvenheimo, J.; Montestruque, S.; Sun, J.; Elliott, G.; Thomas, J.; Ferbas, J.; Kern, B.; Briddell, R.; Leonard, J.; Cesano, A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res., 2003, 9 (10 Pt 2), 3982S-90S.
42. Dörner, T.; Kaufmann, J.; Wegener, W.; Teoh, N.; Goldenberg, D.; Burmester, G. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther., 2006, 8 (3), R74.
43. Jacobi, A.; Goldenberg, D.; Hiepe, F.; Radbruch, A.; Burmester, G.; Dörner, T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis., 2008, 67 (4), 450-7.
44. Steinfeld, S.; Tant, L.; Burmester, G.; Teoh, N.; Wegener, W.; Goldenberg, D.; Pradier, O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res. Ther., 2006, 8 (4), R129.
45. Qu, Z.; Goldenberg, D.; Cardillo, T.; Shi, V.; Hansen, H.; Chang, C. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood, 2008, 111 (4), 2211-9.
46. Litinskiy, M.; Nardelli, B.; Hilbert, D.; He, B.; Schaffer, A.; Casali, P.; Cerutti, A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol., 2002, 3 (9), 822-9.
47. Scapini, P.; Nardelli, B.; Nadali, G.; Calzetti, F.; Pizzolo, G.; Montecucco, C.; Cassatella, M. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J. Exp. Med., 2003, 197 (3), 297-302.
48. Ng, L.; Sutherland, A.; Newton, R.; Qian, F.; Cachero, T.; Scott, M.; Thompson, J.; Wheway, J.; Chtanova, T.; Groom, J.; Sutton, I.; Xin, C.; Tangye, S.; Kalled, S.; Mackay, F.; Mackay, C. B cellactivating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol., 2004, 173 (2), 807-17.
49. von Bülow, G.; van Deursen, J.; Bram, R. Regulation of the Tindependent humoral response by TACI. Immunity, 2001, 14 (5), 573-82.
50. Seshasayee, D.; Valdez, P.; Yan, M.; Dixit, V.; Tumas, D.; Grewal, I. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity, 2003, 18(2), 279-88.
51. Treml, L.; Crowley, J.; Cancro, M. BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells. Semin. Immunol., 2006, 18 (5), 297-304.
52. Gross, J.; Dillon, S.; Mudri, S.; Johnston, J.; Littau, A.; Roque, R.; Rixon, M.; Schou, O.; Foley, K.; Haugen, H.; McMillen, S.; Waggie, K.; Schreckhise, R.; Shoemaker, K.; Vu, T.; Moore, M.; Grossman, A.; Clegg, C. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity, 2001, 15 (2), 289-302.
53. Stohl, W.; Metyas, S.; Tan, S.; Cheema, G.; Oamar, B.; Xu, D.; Roschke, V.; Wu, Y.; Baker, K.; Hilbert, D. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum., 2003, 48 (12), 3475-86.
54. Stohl, W. SLE - systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res. Ther., 2003, 5 (3), 136-8.
55. Cambridge, G.; Stohl, W.; Leandro, M.; Migone, T.; Hilbert, D.; Edwards, J. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum., 2006, 54 (3), 723-32.
56. Lavie, F.; Miceli-Richard, C.; Ittah, M.; Sellam, J.; Gottenberg, J.; Mariette, X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis., 2007, 66 (5), 700-3.
57. Vallerskog, T.; Heimbürger, M.; Gunnarsson, I.; Zhou, W.; Wahren-Herlenius, M.; Trollmo, C.; Malmström, V. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther., 2006, 8 (6), R167.
58. Mackay, F.; Ambrose, C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev., 2003, 14 (3-4), 311-24.
59. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to Blymphocyte stimulator. Drugs R D, 2008, 9 (3), 197-202.
60. Lee, C.; Hymowitz, S.; Wallweber, H.; Gordon, N.; Billeci, K.; Tsai, S.; Compaan, D.; Yin, J.; Gong, Q.; Kelley, R.; DeForge, L.; Martin, F.; Starovasnik, M.; Fuh, G. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood, 2006, 108 (9), 3103-11.
61. Lin, W.; Gong, Q.; Seshasayee, D.; Lin, Z.; Ou, Q.; Ye, S.; Suto, E.; Shu, J.; Lee, W.; Lee, C.; Fuh, G.; Leabman, M.; Iyer, S.; Howell, K.; Gelzleichter, T.; Beyer, J.; Danilenko, D.; Yeh, S.; De-Forge, L.; Ebens, A.; Thompson, J.; Ambrose, C.; Balazs, M.; Starovasnik, M.; Martin, F. Anti-BR3 antibodies: a new class of Bcell immunotherapy combining cellular depletion and survival blockade. Blood, 2007, 110 (12), 3959-67.
62. Brennan, D.; Yui, M.; Wuthrich, R.; Kelley, V. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J. Immunol., 1989, 143 (11), 3470-5.
63. Jacob, C.; McDevitt, H. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature, 1988, 331 (6154), 356-8.
64. Edwards, C. r.; Zhou, T.; Zhang, J.; Baker, T.; De, M.; Long, R.; Borcherding, D.; Bowlin, T.; Bluethmann, H.; Mountz, J. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J. Immunol., 1996, 157 (4), 1758-72.
65. Yokoyama, H.; Kreft, B.; Kelley, V. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int., 1995, 47 (1), 122-30.
66. Aringer, M.; Smolen, J. SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res. Ther., 2003, 5 (4), 172-7.
67. Gabay, C.; Cakir, N.; Moral, F.; Roux-Lombard, P.; Meyer, O.; Dayer, J.; Vischer, T.; Yazici, H.; Guerne, P. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol., 1997, 24 (2), 303-8.
68. Lacki, J.; Leszczynski, P.; Kelemen, J.; Müller, W.; Mackiewicz, S. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J. Med., 1997, 28 (1-2), 99-107.
69. Studnicka-Benke, A.; Steiner, G.; Petera, P.; Smolen, J. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br. J. Rheumatol., 1996, 35 (11), 1067-74.
70. Aderka, D.; Wysenbeek, A.; Engelmann, H.; Cope, A.; Brennan, F.; Molad, Y.; Hornik, V.; Levo, Y.; Maini, R.; Feldmann, M. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum., 1993, 36 (8), 1111-20.
71. Charles, P.; Smeenk, R.; De Jong, J.; Feldmann, M.; Maini, R. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum., 2000, 43 (11), 2383-90.
72. De Rycke, L.; Kruithof, E.; Van Damme, N.; Hoffman, I.; Van den Bossche, N.; Van den Bosch, F.; Veys, E.; De Keyser, F. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum., 2003, 48 (4), 1015-23.
73. Shakoor, N.; Michalska, M.; Harris, C.; Block, J. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 2002, 359 (9306), 579-80.
74. Carlson, E.; Rothfield, N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum., 2003, 48 (4), 1165-6; author reply 1166.
75. Stokes, M.; Foster, K.; Markowitz, G.; Ebrahimi, F.; Hines, W.; Kaufman, D.; Moore, B.; Wolde, D.; D'Agati, V. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol. Dial. Transplant., 2005, 20 (7), 1400-6.
76. Palucka, A.; Blanck, J.; Bennett, L.; Pascual, V.; Banchereau, J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl. Acad. Sci. U S A, 2005, 102 (9), 3372-7.
77. Via, C.; Shustov, A.; Rus, V.; Lang, T.; Nguyen, P.; Finkelman, F. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol., 2001, 167 (12), 6821-6.
78. Cope, A.; Londei, M.; Chu, N.; Cohen, S.; Elliott, M.; Brennan, F.; Maini, R.; Feldmann, M. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest., 1994, 94 (2), 749-60.
79. Casciola-Rosen, L.; Rosen, A.; Petri, M.; Schlissel, M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl. Acad. Sci. U S A, 1996, 93 (4), 1624-9.
80. Aringer, M.; Steiner, G.; Graninger, W.; Höfler, E.; Steiner, C.; Smolen, J. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum., 2007, 56 (1), 274-9.
81. Hayat, S.; Uppal, S. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod. Rheumatol., 2007, 17 (2), 174-7.
82. Horai, R.; Saijo, S.; Tanioka, H.; Nakae, S.; Sudo, K.; Okahara, A.; Ikuse, T.; Asano, M.; Iwakura, Y. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med., 2000, 191 (2), 313-20.
83. Takemura, T.; Yoshioka, K.; Murakami, K.; Akano, N.; Okada, M.; Aya, N.; Maki, S. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch., 1994, 424 (5), 459-64.
84. Sturfelt, G.; Roux-Lombard, P.; Wollheim, F.; Dayer, J. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br. J. Rheumatol., 1997, 36 (12), 1283-9.
85. Suzuki, H.; Takemura, H.; Kashiwagi, H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum., 1995, 38 (8), 1055-9.
86. Kiberd, B.; Stadnyk, A. Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology, 1995, 30 (2), 131-7.
87. Ostendorf, B.; Iking-Konert, C.; Kurz, K.; Jung, G.; Sander, O.; Schneider, M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis., 2005, 64 (4), 630-3.
88. Stuart, R.; Littlewood, A.; Maddison, P.; Hall, N. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin. Exp. Rheumatol., 13 (1), 17-22.
89. Horii, Y.; Iwano, M.; Hirata, E.; Shiiki, M.; Fujii, Y.; Dohi, K.; Ishikawa, H. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int. Suppl., 1993, 39, S71-5.
90. Yoshio, T.; Masuyama, J.; Kohda, N.; Hirata, D.; Sato, H.; Iwamoto, M.; Mimori, A.; Takeda, A.; Minota, S.; Kano, S. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J. Rheumatol., 1997, 24 (3), 489-95.
91. Alcocer-Varela, J.; Aleman-Hoey, D.; Alarcon-Segovia, D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus, 1992, 1 (2), 111-7.
92. Kiberd, B. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J. Am. Soc. Nephrol., 1993, 4 (1), 58-61.
93. Mihara, M.; Kasutani, K.; Okazaki, M.; Nakamura, A.; Kawai, S.; Sugimoto, M.; Matsumoto, Y.; Ohsugi, Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int. Immunopharmacol., 2005, 5 (12), 1731-40.
94. Nishimoto, N.; Yoshizaki, K.; Miyasaka, N.; Yamamoto, K.; Kawai, S.; Takeuchi, T.; Hashimoto, J.; Azuma, J.; Kishimoto, T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum., 2004, 50 (6), 1761-9.
95. Ito, H.; Takazoe, M.; Fukuda, Y.; Hibi, T.; Kusugami, K.; Andoh, A.; Matsumoto, T.; Yamamura, T.; Azuma, J.; Nishimoto, N.; Yoshizaki, K.; Shimoyama, T.; Kishimoto, T. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology, 2004, 126 (4), 989-96; discussion 947.
96. Nishimoto, N.; Sasai, M.; Shima, Y.; Nakagawa, M.; Matsumoto, T.; Shirai, T.; Kishimoto, T.; Yoshizaki, K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood, 2000, 95 (1), 56-61.
97. Yokota, S.; Miyamae, T.; Imagawa, T.; Iwata, N.; Katakura, S.; Mori, M.; Woo, P.; Nishimoto, N.; Yoshizaki, K.; Kishimoto, T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum., 2005, 52 (3), 818-25.
98. Ishida, H.; Muchamuel, T.; Sakaguchi, S.; Andrade, S.; Menon, S.; Howard, M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med., 1994, 179 (1), 305-10.
99. Yin, Z.; Bahtiyar, G.; Zhang, N.; Liu, L.; Zhu, P.; Robert, M.; McNiff, J.; Madaio, M.; Craft, J. IL-10 regulates murine lupus. J. Immunol., 2002, 169 (4), 2148-55.
100. Houssiau, F.; Lefebvre, C.; Vanden Berghe, M.; Lambert, M.; Devogelaer, J.; Renauld, J. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus, 1995, 4 (5), 393-5.
101. Llorente, L.; Richaud-Patin, Y.; Couderc, J.; Alarcon-Segovia, D.; Ruiz-Soto, R.; Alcocer-Castillejos, N.; Alcocer-Varela, J.; Granados, J.; Bahena, S.; Galanaud, P.; Emilie, D. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum., 1997, 40 (8), 1429-35.
102. Llorente, L.; Zou, W.; Levy, Y.; Richaud-Patin, Y.; Wijdenes, J.; Alcocer-Varela, J.; Morel-Fourrier, B.; Brouet, J.; Alarcon-Segovia, D.; Galanaud, P.; Emilie, D. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med., 1995, 181 (3), 839-44.
103. Llorente, L.; Richaud-Patin, Y.; García-Padilla, C.; Claret, E.; Jakez-Ocampo, J.; Cardiel, M.; Alcocer-Varela, J.; Grangeot-Keros, L.; Alarcón-Segovia, D.; Wijdenes, J.; Galanaud, P.; Emilie, D. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum., 2000, 43 (8), 1790-800.
104. Colonna, M.; Trinchieri, G.; Liu, Y. Plasmacytoid dendritic cells in immunity. Nat. Immunol., 2004, 5 (12), 1219-26.
105. Feng, X.; Wu, H.; Grossman, J.; Hanvivadhanakul, P.; FitzGerald, J.; Park, G.; Dong, X.; Chen, W.; Kim, M.; Weng, H.; Furst, D.; Gorn, A.; McMahon, M.; Taylor, M.; Brahn, E.; Hahn, B.; Tsao, B. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum., 2006, 54 (9), 2951-62.
106. Baechler, E.; Batliwalla, F.; Karypis, G.; Gaffney, P.; Ortmann, W.; Espe, K.; Shark, K.; Grande, W.; Hughes, K.; Kapur, V.; Gre gersen, P.; Behrens, T. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U S A, 2003, 100 (5), 2610-5.
107. Bengtsson, A.; Sturfelt, G.; Truedsson, L.; Blomberg, J.; Alm, G.; Vallin, H.; Rönnblom, L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus, 2000, 9 (9), 664-71.
108. Balomenos, D.; Rumold, R.; Theofilopoulos, A. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest., 1998, 101 (2), 364-71.
109. Jacob, C.; van der Meide, P.; McDevitt, H. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J. Exp. Med., 1987, 166 (3), 798-803.
110. Lawson, B.; Prud'homme, G.; Chang, Y.; Gardner, H.; Kuan, J.; Kono, D.; Theofilopoulos, A. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J. Clin. Invest., 2000, 106 (2), 207-15.
111. Nicoletti, F.; Di Marco, R.; Zaccone, P.; Xiang, M.; Magro, G.; Grasso, S.; Morrone, S.; Santoni, A.; Shoenfeld, Y.; Garotta, G.; Meroni, P. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice. Eur. J. Immunol., 2000, 30 (2), 438-47.
112. Uhm, W.; Na, K.; Song, G.; Jung, S.; Lee, T.; Park, M.; Yoo, D. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford), 2003, 42 (8), 935-8.
113. Min, D.; Cho, M.; Cho, C.; Min, S.; Kim, W.; Yang, S.; Min, J.; Hong, Y.; Lee, S.; Park, S.; Kim, H. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand. J. Rheumatol., 2001, 30 (3), 159-63.
114. Thompson, C.; Lindsten, T.; Ledbetter, J.; Kunkel, S.; Young, H.; Emerson, S.; Leiden, J.; June, C., CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. U S A, 1989, 86 (4), 1333-7.
115. Marengère, L.; Waterhouse, P.; Duncan, G.; Mittrücker, H.; Feng, G.; Mak, T. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science, 1996, 272 (5265), 1170-3.
116. Chuang, E.; Fisher, T.; Morgan, R.; Robbins, M.; Duerr, J.; Vander Heiden, M.; Gardner, J.; Hambor, J.; Neveu, M.; Thompson, C. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity, 2000, 13 (3), 313-22.
117. Alegre, M.; Shiels, H.; Thompson, C.; Gajewski, T. Expression and function of CTLA-4 in Th1 and Th2 cells. J. Immunol., 1998, 161 (7), 3347-56.
118. Freeman, G.; Gray, G.; Gimmi, C.; Lombard, D.; Zhou, L.; White, M.; Fingeroth, J.; Gribben, J.; Nadler, L. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med., 1991, 174 (3), 625-31.
119. Pentcheva-Hoang, T.; Egen, J.; Wojnoonski, K.; Allison, J. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity, 2004, 21 (3), 401-13.
120. Emery, P. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin. Investig. Drugs, 2003, 12 (4), 673-81.
121. Judge, T.; Tang, A.; Spain, L.; Deans-Gratiot, J.; Sayegh, M.; Turka, L. The in vivo mechanism of action of CTLA4Ig. J. Immunol., 1996, 156 (6), 2294-9.
122. Mirenda, V.; Jarmin, S.; David, R.; Dyson, J.; Scott, D.; Gu, Y.; Lechler, R.; Okkenhaug, K.; Marelli-Berg, F. Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood, 2007, 109 (7), 2968-77.
123. Ramanujam, M.; Wang, X.; Huang, W.; Schiffer, L.; Grimaldi, C.; Akkerman, A.; Diamond, B.; Madaio, M.; Davidson, A. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol., 2004, 173 (5), 3524-34.
124. Mackie, S.; Vital, E.; Ponchel, F.; Emery, P. Co-stimulatory blockade as therapy for rheumatoid arthritis. Curr. Rheumatol. Rep., 2005, 7 (5), 400-6.
125. Kremer, J.; Dougados, M.; Emery, P.; Durez, P.; Sibilia, J.; Shergy, W.; Steinfeld, S.; Tindall, E.; Becker, J.; Li, T.; Nuamah, I.; Aranda, R.; Moreland, L. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum., 2005, 52 (8), 2263-71.
126. Salomon, B.; Bluestone, J. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 2001, 19, 225-52.
127. Vincenti, F.; Larsen, C.; Durrbach, A.; Wekerle, T.; Nashan, B.; Blancho, G.; Lang, P.; Grinyo, J.; Halloran, P.; Solez, K.; Hagerty, D.; Levy, E.; Zhou, W.; Natarajan, K.; Charpentier, B. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med., 2005, 353 (8), 770-81.
128. Grammer, A.; Slota, R.; Fischer, R.; Gur, H.; Girschick, H.; Yarboro, C.; Illei, G.; Lipsky, P. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest., 2003, 112 (10), 1506-20.
129. Kalled, S.; Cutler, A.; Datta, S.; Thomas, D. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol., 1998, 160 (5), 2158-65.
130. Davis, J. J.; Totoritis, M.; Rosenberg, J.; Sklenar, T.; Wofsy, D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol., 2001, 28 (1), 95-101.
131. Yellin, M.; D'Agati, V.; Parkinson, G.; Han, A.; Szema, A.; Baum, D.; Estes, D.; Szabolcs, M.; Chess, L. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum., 1997, 40 (1), 124-34.
132. Wang, X.; Huang, W.; Mihara, M.; Sinha, J.; Davidson, A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J. Immunol., 2002, 168 (4), 2046-53.
133. Huang, W.; Sinha, J.; Newman, J.; Reddy, B.; Budhai, L.; Furie, R.; Vaishnaw, A.; Davidson, A. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum., 2002, 46 (6), 1554-62.
134. Freedman, J. CD40 ligand - assessing risk instead of damage? N. Engl. J. Med., 2003, 348 (12), 1163-5.
135. Kalunian, K.; Davis, J. J.; Merrill, J.; Totoritis, M.; Wofsy, D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2002, 46 (12), 3251-8.
136. Boumpas, D.; Furie, R.; Manzi, S.; Illei, G.; Wallace, D.; Balow, J.; Vaishnaw, A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum., 2003, 48 (3), 719-27.
137. Daikh, D.; Finck, B.; Linsley, P.; Hollenbaugh, D.; Wofsy, D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol., 1997, 159 (7), 3104-8.
138. Hutloff, A.; Büchner, K.; Reiter, K.; Baelde, H.; Odendahl, M.; Jacobi, A.; Dörner, T.; Kroczek, R. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum., 2004, 50 (10), 3211-20.
139. Gonzalo, J.; Delaney, T.; Corcoran, J.; Goodearl, A.; Gutierrez-Ramos, J.; Coyle, A. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J. Immunol., 2001, 166 (1), 1-5.
140. Kawamoto, M.; Harigai, M.; Hara, M.; Kawaguchi, Y.; Tezuka, K.; Tanaka, M.; Sugiura, T.; Katsumata, Y.; Fukasawa, C.; Ichida, H.; Higami, S.; Kamatani, N. Expression and function of inducible costimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-doublestranded DNA antibody production. Arthritis Res. Ther., 2006, 8 (3), R62.
141. Iwai, H.; Abe, M.; Hirose, S.; Tsushima, F.; Tezuka, K.; Akiba, H.; Yagita, H.; Okumura, K.; Kohsaka, H.; Miyasaka, N.; Azuma, M. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J. Immunol., 2003, 171 (6), 2848-54.
142. DeBenedette, M.; Wen, T.; Bachmann, M.; Ohashi, P.; Barber, B.; Stocking, K.; Peschon, J.; Watts, T. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cyto toxic T cell response to influenza virus. J. Immunol., 1999, 163 (9), 4833-41.
143. Sun, Y.; Chen, H.; Subudhi, S.; Chen, J.; Koka, R.; Chen, L.; Fu, Y. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med., 2002, 8 (12), 1405-13.
144. Foell, J.; Strahotin, S.; O'Neil, S.; McCausland, M.; Suwyn, C.; Haber, M.; Chander, P.; Bapat, A.; Yan, X.; Chiorazzi, N.; Hoffmann, M.; Mittler, R. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J. Clin. Invest., 2003, 111 (10), 1505-18.
145. Mittler, R.; Foell, J.; McCausland, M.; Strahotin, S.; Niu, L.; Bapat, A.; Hewes, L. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol. Res., 2004, 29 (1-3), 197-208.
146. Choi, B.; Bae, J.; Choi, E.; Kang, W.; Sakaguchi, S.; Vinay, D.; Kwon, B. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J. Leukoc. Biol., 2004, 75 (5), 785-91.
147. Clayton, T.; Ogden, S.; Goodfield, M. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J. Am. Acad. Dermatol., 2006, 54 (5), 892-5.
148. Usmani, N.; Goodfield, M. Efalizumab in the treatment of discoid lupus erythematosus. Arch. Dermatol., 2007, 143 (7), 873-7.
149. Abe, K.; Miyazaki, M.; Koji, T.; Furusu, A.; Nakamura-Kurashige, T.; Nishino, T.; Ozono, Y.; Harada, T.; Sakai, H.; Kohno, S. Enhanced expression of complement C5a receptor mRNA in human diseased kidney assessed by in situ hybridization. Kidney Int., 2001, 60 (1), 137-46.
150. Wang, Y.; Hu, Q.; Madri, J.; Rollins, S.; Chodera, A.; Matis, L. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. U S A, 1996, 93 (16), 8563-8.
151. Bao, L.; Osawe, I.; Puri, T.; Lambris, J.; Haas, M.; Quigg, R. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur. J. Immunol., 2005, 35 (8), 2496-506.
152. Iking-Konert, C.; Stocks, S.; Weinsberg, F.; Engelbrecht, R.; Bleck, E.; Perniok, A.; Fischer-Betz, R.; Pincus, S.; Nardone, L.; Schneider, M. First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigenheteropolymer ETI-104. Ann. Rheum. Dis., 2004, 63 (9), 1104-12.
153. St Clair, E. The calm after the cytokine storm: lessons from the TGN1412 trial. J. Clin. Invest., 2008, 118 (4), 1344-7.
154. Stebbings, R.; Findlay, L.; Edwards, C.; Eastwood, D.; Bird, C.; North, D.; Mistry, Y.; Dilger, P.; Liefooghe, E.; Cludts, I.; Fox, B.; Tarrant, G.; Robinson, J.; Meager, T.; Dolman, C.; Thorpe, S.; Bristow, A.; Wadhwa, M.; Thorpe, R.; Poole, S. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol., 2007, 179 (5), 3325-31.
155. Nguyen, D.; Hurtado-Ziola, N.; Gagneux, P.; Varki, A. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA, 2006, 103 (20), 7765-70.
156. Gaston, R.; Deierhoi, M.; Patterson, T.; Prasthofer, E.; Julian, B.; Barber, W.; Laskow, D.; Diethelm, A.; Curtis, J. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int., 1991, 39 (1), 141-8.
157. Khoury, S.; Sayegh, M. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity, 2004, 20 (5), 529-38.
158. Burkly, L. CD40 pathway blockade as an approach to immunotherapy. Adv. Exp. Med. Biol., 2001, 489, 135-52.
159. Bennett, C.; Christie, J.; Ramsdell, F.; Brunkow, M.; Ferguson, P.; Whitesell, L.; Kelly, T.; Saulsbury, F.; Chance, P.; Ochs, H. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet., 2001, 27 (1), 20-1.
160. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 1995, 155 (3), 1151-64.